NDLI: Serum follistatin in patients with prostate cancer metastatic to the bone

Content Provider	Springer Nature Link
Author	Tumminello, Francesca Maria Badalamenti, Giuseppe Fulfaro, Fabio Incorvaia, Lorena Cresciman, Marilena Flandina, Carla Sepporta, Maria Vittoria Leto, Gaeta
Copyright Year	2010
Abstract	The clinical significance of circulating follistatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M+) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy subjects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Conversely, in BPH patients, FLST levels resulted lower than in HS (P = 0.025). In cancer patients the serum concentrations of FLST significantly correlated with the presence of bone metastases (P = 0.0005) or increased PSA levels (P = 0.04). Interestingly, significant differences in the ratio between FLST and Act A serum concentrations (FLST/Act A) were observed between HS and BPH patients (P = 0.001) or PCa patients (P = 0.0005). Finally, ROC curve analysis, highlighted a sound diagnostic performance of FLST in detecting M+ patients (P = 0.0001). However, the diagnostic effectiveness of FLST did not result significantly superior to that of Act A or PSA. These findings suggest that FLST may be regarded as a potential, molecular target in the treatment of metastatic bone disease while its clinical role as soluble marker in the clinical management of PCa patients with bone metastases needs to be better defined.
Starting Page	549
Ending Page	555
Page Count	7
File Format	PDF
ISSN	02620898
Journal	Clinical & Experimental Metastasis
Volume Number	27
Issue Number	8
e-ISSN	15737276
Language	English
Publisher	Springer Netherlands
Publisher Date	2010-07-11
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Activin Bone metastasis Cancer Follistatin Prostate cancer Transforming growth factor β Tumor markers Surgical Oncology Hematology Oncology Biomedicine general Cancer Research
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

Endoglin suppresses human prostate cancer metastasis

Luminal breast cancer metastasis is dependent on estrogen signaling

TGF-β and BMP7 interactions in tumour progression and bone metastasis

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis

Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling

Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse

Serum follistatin in patients with prostate cancer metastatic to the bone

Similar Documents

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

Endoglin suppresses human prostate cancer metastasis

Luminal breast cancer metastasis is dependent on estrogen signaling

TGF-β and BMP7 interactions in tumour progression and bone metastasis

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer

Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis

Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling

Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse

Serum follistatin in patients with prostate cancer metastatic to the bone